• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tourmaline Bio, Inc. - Common Stock (NQ: TRML )

    26.73 +0.48 (+1.83%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 242,193
    Open 26.74
    Bid (Size) 26.20 (1)
    Ask (Size) 27.10 (1)
    Prev. Close 26.25
    Today's Range 26.01 - 27.00
    52wk Range 9.180 - 48.31
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tourmaline Bio to Present at Upcoming Investor Conferences
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024
    TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +0.87%
    +0.87%
    1 Month
    +63.49%
    +63.49%
    3 Month
    +113.33%
    +113.33%
    6 Month
    +18.22%
    +18.22%
    1 Year
    +145.23%
    +145.23%

    More News

    Read More
    Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023
    Via InvestorPlace
    Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024
    Via InvestorPlace
    Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
    From Avalo Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Dow Jumps 200 Points; US Weekly Jobless Claims Fall
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    Tourmaline Bio Announces Pricing of Public Offering of Common Stock
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Tourmaline Bio Announces Proposed Public Offering of Common Stock
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
    From Tourmaline Bio, Inc.
    Via GlobeNewswire
    TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
    Via MarketBeat
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.